Five things for pharma marketers to know: Tuesday, April 5, 2016
1. Valeant terminated the sales force for Addyi, the female sexual-desire drug it acquired in August for $1 billion, sources told Bloomberg. The drug has not been widely adopted in its first six months on the market, but the company plans to launch a new sales strategy. (Bloomberg)
2. The Treasury Department issued new rules that put a three-year limit on foreign companies buying up U.S. assets to avoid ownership limits in future inversion deals. At stake is Pfizer's $160 billion merger with Allergan. (Reuters)
3. MannKind purchased the marketing rights to Afrezza, the inhaled insulin it developed. Sanofi is no longer the marketing partner for the product.
4. Pfizer said Xeljanz, its rheumatoid arthritis drug, met its primary endpoints in a new trial, with the drug performing better than placebo at three months when treating patients with psoriatic arthritis. Xeljanz is an oral drug.
5. The Philippines launched the first public immunization program for dengue fever. Sanofi's vaccine, called Dengvaxia, received its first approval in December in Mexico. (AP)